The Biolocity Team is excited to partner with Additional Ventures to assist in identifying promising research at both Georgia Tech and Emory University that provides solutions for single ventricle heart defects. To learn about this partnership, read more here.
The Biolocity team is excited to announce the successful license of AngioCloud, a web-based software for the treatment of brain aneurysms, by 11Ten Innovation Partners. Their technology and team are an excellent example of the success that can come from collaborations between clinicians and software engineers. This is also an opportunity where Biolocity engaged the Emory Healthcare Innovation Hub to curate the commercial opportunity for AngioCloud and source the licensing opportunity.
AngioCloud is a graduate of the Coulter program (now Biolocity), which provides funding and commercialization guidance to patient-impacting university technologies. During their time as a funded technology team, Biolocity provided financial and consulting support for prototype development and quality systems for the AngioCloud technology. “We applied with the idea that funding would be the primary determinant necessary for our success. What we learned is that the guidance, advocacy, mentorship, and regulatory resources received were every bit as critical, said Frank Tong, MD, AngioCloud co-inventor. “Our team is profoundly grateful to the Biolocity team for their guidance in translating a technical idea into a real world clinical resource that will soon benefit patients.”
“The Emory Healthcare Innovation Hub is focused on developing and commercializing technologies that make an impact on healthcare cost, quality, and access. As such, we are very excited to announce that we have licensed AngioCloud, an interventional radiology 3D imaging platform that uses computational algorithms to calculate the specifications of implantable devices”, said Will ElLaissi, Director of the Emory Healthcare Innovation Hub. “This technology helps device OEMs manage inventory and customize offerings and gives Neuro-Interventionalists the tools they need to pick the right device so that they can maximize outcomes and reduce costs.”
Biolocity is thrilled to partner our portfolio project, AngioCloud, with the Emory Healthcare Innovation Hub. “This is a great example of complimentary programs and resources working together at Emory to accelerate medical technologies to the market,” Shawna Khouri, Managing Director of Biolocity.
To learn more about AngioCloud, visit: http://www.ott.emory.edu/industry/featured/angiocloud.html
ABOUT BIOLOCITY
Biolocity is a philanthropic, multi-institutional program that accelerates the commercialization of medical technologies with intellectual property held at Emory University and/or Georgia Institute of Technology. Biolocity utilizes the Coulter Process: a combination of grant funding, education, and operational business expertise to de-risk academic innovations and translate them to the private sector. In the last five years, Biolocity’s 40 portfolio technologies have resulted in 20 start-ups, two industry partnerships, and three products on the market.
Faculty at Georgia Tech, Emory University, and Georgia State University have been selected to receive a broad range of support from Biolocity to accelerate the commercialization of their patient impacting technologies. During their funding period, each team will receive project management and work directly with business experts and consultants to de-risk their technology and advance its development. [Read more…] about Technologies Selected for Biolocity Commercialization Funding
Biolocity stems from the expansion of a successful five year pilot in which the program awarded over $6.2 million to 40 innovative projects leading to 20 start-ups, and three products on the market. As a result of the Coulter Fund’s successful pilot and the increasing demands for translational funding and mentorship, Biolocity was created to address the need for a broader network of support for university innovators.
“Biolocity extends our successful Coulter Translational Program model to reach a larger, more diverse cohort of innovators at earlier stages of their discovery, guides them using our successful experts-in-residence process, and cultivates individualized links with the commercialization ecosystem,” said Susan Margulies, Chair of the Wallace H. Coulter Department of Biomedical Engineering.
Similar to the Coulter program, Biolocity provides university innovators with a combination of investment, resources, and guidance that early-stage medical technologies need to reach critical commercialization milestones. We utilize three collaborative methods to advance translational science to the marketplace:
Bringing both the experience and success of the Coulter process, Biolocity creates a multi-institutional network to support the commercialization of medical technology in the southeast. The program adds new connectivity across Atlanta, while deepening its commitment to Emory University and the Georgia Institute of Technology.
“We are grateful to the Coulter Foundation’s support our pilot and proud of our teams’ successes”, said Shawna Khouri, managing director of Biolocity. “As our program evolves and continues to grow as Biolocity, we look forward to expanding our network with new partners and adding connections within the Atlanta biotech ecosystem.”
To learn more about Biolocity’s upcoming funding cycle and educational opportunities, visit www.biolocity.org.
The Coulter Program released its first annual report in 2018 highlighting the program’s success over the past four years. The 2018 Coulter Translational Program Annual Report is available here.
